Andersen Morten, Trapani Davide, Ravn Jesper, Sørensen Jens Benn, Andersen Claus Bøgelund, Grauslund Morten, Santoni-Rugiu Eric
Department of Pathology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Department of Thoracic Surgery, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Anticancer Res. 2015 Nov;35(11):6223-9.
BACKGROUND/AIM: We recently reported that miR-126 is down-regulated in malignant pleural mesothelioma (MPM) and can be combined into a 4-microRNA-classifier that can accurately diagnose MPM with high sensitivity and specificity. Herein we analyzed the epigenetic regulation of miR-126 and its host gene EGF-like domain, multiple 7 (EGFL7).
Resected formalin-fixed paraffin-embedded MPM tissues from 29 patients, 14 patient-matched non-neoplastic pleura (NNP) specimens, 5 MPM diagnostic biopsies (DB), and 5 samples of pneumothorax-induced benign reactive mesothelial proliferation (PTHX) were analyzed. miR-126 and EGFL7 mRNA were quantified by RT-qPCR. CpG-islands' methylation in the EGFL7 promoter was analyzed using methylation-specific PCR and in the MIR126-containing intron 7 was quantified by pyrosequencing.
Relative to NNP, EGFL7 was under-expressed more than 4-fold in MPM (p<0.001). EGFL7 mRNA and miR-126 levels correlated in MPM (p<0.01) and NNP (p<0.001). The EGFL7 promoter region was hypermethylated in 69% of MPM and 80% of DB samples, but not in NNP and PTHX samples. EGFL7 promoter hypermethylation was associated with epithelioid histology (p<0.05) and reduced patient-survival (p<0.05).
In MPM, DNA-hypermethylation down-regulates miR-126 and its host gene EGFL7, therefore is a poor prognostic factor, and may represent a future therapeutic target for de-methylating strategies re-establishing EGFL7 and miR-126 expression.
背景/目的:我们最近报道,微小RNA-126(miR-126)在恶性胸膜间皮瘤(MPM)中表达下调,并且可以被整合到一个能以高灵敏度和特异性准确诊断MPM的四微小RNA分类器中。在此,我们分析了miR-126及其宿主基因表皮生长因子样结构域7(EGFL7)的表观遗传调控。
分析了29例患者切除的经福尔马林固定、石蜡包埋的MPM组织、14例患者匹配的非肿瘤性胸膜(NNP)标本、5例MPM诊断性活检(DB)以及5例气胸诱导的良性反应性间皮增生(PTHX)样本。通过逆转录定量聚合酶链反应(RT-qPCR)对miR-126和EGFL7信使核糖核酸(mRNA)进行定量分析。使用甲基化特异性聚合酶链反应分析EGFL7启动子中的CpG岛甲基化,并通过焦磷酸测序对包含MIR126的内含子7中的甲基化进行定量分析。
相对于NNP,EGFL7在MPM中的表达下调超过4倍(p<0.001)。EGFL7 mRNA和miR-126水平在MPM(p<0.01)和NNP(p<0.001)中存在相关性。在69%的MPM和80%的DB样本中,EGFL7启动子区域发生高甲基化,但在NNP和PTHX样本中未发生。EGFL7启动子高甲基化与上皮样组织学(p<0.05)及患者生存率降低(p<0.05)相关。
在MPM中,DNA高甲基化下调miR-126及其宿主基因EGFL7,因此是一个不良预后因素,可能代表一种通过去甲基化策略重新建立EGFL7和miR-126表达的未来治疗靶点。